With box warnings

Without box warnings

Branded

Generic

2 results

beyfortus
(nirsevimab)
Sanofi Pasteur Inc.
Usage: BEYFORTUS is indicated for preventing Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season, and in children up to 24 months who are vulnerable to severe RSV disease during their second RSV season.
synagis
(palivizumab)
Swedish Orphan Biovitrum AB (publ)
Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients: 1) born prematurely (≤35 weeks) and ≤6 months at RSV season start; 2) with BPD requiring treatment and ≤24 months; 3) with significant CHD and ≤24 months at RSV season start.

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody class drugs

beyfortus